Three Companies, One Platform

The $10 million will fund two additional acquisitions, to be announced in coming months. Procode intends to follow the same playbook it used with The Auctus Group: acquire the best surgical billing companies and layer in Procode’s AI to drive better outcomes for surgeons:

• Procode: AI coding for surgery that automates the coding workflow from charge capture to submission, reduces coding-related denials, and fully captures reimbursements
• Procollect: An operating system for billing teams with native reporting, AI support and automation that reduces days in AR and accelerates reimbursements
• Auctus Provider App: An app that puts real-time financial data at Procode’s clients’ fingertips

“We’re on track to double The Auctus Group’s revenue and quintuple its EBITDA margin,” said Jeff Cripe, CEO of Procode. “That matters because we bill on contingency — we only get paid when our clients get paid — so our growth is proof our AI is putting more dollars in providers’ pockets, not just automating paperwork. Large health systems have had incredible technology companies innovating on their most pressing problems for years. We’re proud to innovate on behalf of the massive, long tail of RCM companies serving private practice surgeons.”

Procode AI Outperforms Professional Coders and Major LLMs

The retrospective comparative study published in PRS Global Open, “Artificial Intelligence for Automated CPT Coding in Plastic and Reconstructive Surgery Using a Fine-Tuned Hybrid LLM,” compared Procode AI’s fine-tuned hybrid LLM against OpenAI GPT-5, Google Gemini 2.5 Pro, Anthropic Claude Sonnet 4.5, and external professional auditors in reviewing operative reports at three different difficulty levels. A total of 120 case reports were analyzed (40 Easy difficulty, 40 Medium, 40 High).

Procode achieved 86.7% overall accuracy — more than double the best-performing LLM (OpenAI, 35.8%) and more than twice the accuracy of human auditors (42.5%). On easy cases, Procode was perfect: 100%. On the hardest cases (defined as including 4 or more CPT codes), it achieved 80% while general-purpose LLMs ranged from 5% to 12.5%.

“Our research shows that AI trained specifically for surgical coding can reliably outperform both humans and generic models,” said Kameron Rezzadeh, MD, FACS, cofounder and Chief Medical Officer of Procode. “That’s a step change in what billing accuracy looks like for private practice surgeons.”

Health Velocity Capital Leads Series A

Grant Blevins, Partner at Health Velocity Capital, said: “Over our careers, we have built deep expertise in revenue cycle management, developed relationships with exceptional billing practice owners, and grown increasingly convinced that this market is ready for a company that can finally deliver true end-to-end automation. Procode is uniquely positioned to do that by giving small billing practice owners a best-in-class AI strategy no traditional buyer can match, while preserving the specialty expertise that made their businesses valuable and building the category-defining RCM platform for private practice surgeons.”

About Procode Inc. Procode is an AI-powered RCM company for surgeons in private practice. Founded in 2024, Procode builds intelligent billing infrastructure that removes administrative burden and maximizes reimbursement, giving surgeons the freedom to focus on patient care. The company has raised $14 million in total venture funding and serves more than 350 plastic surgery and dermatology providers through its acquisition of The Auctus Group.

About Health Velocity Capital Health Velocity Capital invests exclusively in innovative healthcare software and services companies. The firm’s partners have more than 90 collective years as investors, entrepreneurs, and executives helping to finance and build innovative companies that created important new healthcare markets and that became market leaders, including successful companies such as Teladoc, Livongo, Change Healthcare, MDLive, Contessa Health, Headspace Health, Aspire Health, Zipari, IVX Health, Artera (fka Well Health), Compassus, Aperio, The Advisory Board Company, Healthways (Tivity Health), US Renal Care, Spero Health, OnShift, and many others. The firm counts among its limited partners many of the largest and most influential healthcare organizations in the country and current and former senior healthcare executives who collectively represent organizations that insure more than 175 million Americans, operate more than 1,000 hospitals, provide pharmacy and PBM services to everyone in the United States, and sell software to every major US health system.

Peer-reviewed research paper: 
https://journals.lww.com/prsgo/fulltext/10.1097/gox.0000000000007970~artificial-intelligence-for-automated-current-procedural

Download the App iOS: https://apps.apple.com/us/app/auctus-providers/id6751704100

Android: https://play.google.com/store/apps/details?id=com.procodeai.procodeaicompanion&hl=en_US

www.tryprocode.com | auctusgroupconsulting.com

SOURCE Procode Inc.

NEW YORK, July 28, 2026 — ProphetX, America’s first federally regulated sports-native prediction market, today announced the close of a $35 million fundraising round to accelerate its product development, boost liquidity across markets, and scale its B2B platform and partnerships.

The round drew participation from venture, sports, and proprietary trading firms, reflecting broad institutional confidence in ProphetX’s business model. The round was led by Parlay Capital and Data Point Capital, with participation from FDJ Ventures, Greenwave Ventures, Connexa Capital, Impellent Ventures, the Operating Group, and Sharp Alpha Advisors. Chicago Trading Company Ventures, Belvedere Trading, principals at White Swan Data, principals at Consolidated Trading, and Ematiq also made direct investments, signaling significant interest from the professional trading community in the emerging regulated prediction market space.

“On the heels of ProphetX’s recent nationwide launch and CFTC approval to operate as America’s first federally regulated sports-native prediction market, this raise gives us the fuel to meet the surging demand from both consumers and institutions to participate in this new asset class,” said ProphetX CEO and Co-Founder Dean Sisun. “Prediction markets are now a permanent fixture of the American financial landscape, and ProphetX intends to lead them.”

ProphetX previously operated as a sweepstakes platform, and following a successful FIFA World Cup as a federally regulated prediction market, has seen core KPIs including active users and assets on platform increase 50% in its first 30 days of operating. ProphetX is targeting a tripling of trading volume in 2026 driven by B2B partnerships, expanded institutional market coverage, and its proprietary Request for Quote (RFQ) Parlay Mechanism. This raise positions ProphetX to capture a significant share of the fast-growing B2B event contracts market.

Unlike sportsbooks, which are single-dealer models designed to profit when consumers lose, ProphetX is a true peer-to-peer exchange where users set their own prices, trade directly against one another, and pay a thin, transparent commission. ProphetX’s regulated market structure includes an RFQ Parlay Mechanism, which enables users to construct and price multi-event combinations directly with counterparties. The mechanism mirrors institutional trading protocols used in traditional financial markets, delivering flexibility, transparency, and competitive pricing to event-based contracts.

“We are excited to support Dean and the ProphetX team with additional capital to accelerate their next phase of growth as America’s first federally regulated, sports-native prediction market,” said Greg Buonocore, CEO and Managing Partner at Parlay Capital Holdings. “ProphetX is building the industry-leading infrastructure that will define how everyday Americans and institutional investors alike participate in sports prediction markets.”

“ProphetX has established itself as a pioneer in the prediction markets ecosystem, and we are thrilled to participate in this funding round,” said Scott Savitz, Founder and Managing Partner of Data Point Capital. “The company’s innovative approach, combined with its recent CFTC approval and increasing interest in event-based markets, positions it well for long-term growth. We look forward to supporting the team as they continue to execute on their vision.”

About ProphetX:
Founded in 2018, ProphetX is America’s first sports-native prediction market. The company is a regulated U.S. exchange for event-driven contracts, built on a sports-focused foundation and designed to expand across a broad range of event markets. Its mission is to create the world’s most trusted and innovative marketplace where anyone can participate in event outcomes.

Media Contact:
ProphetX Newsroom
[email protected]
https://www.prophetx.co/lobby/news

SOURCE ProphetX

REDWOOD CITY, Calif., July 28, 2026 — Array Labs has raised $21 million in an oversubscribed strategic investment round, anchored by Mitsubishi Electric Corporation, with continued participation from Catapult Ventures, Kompas VC, and Y Combinator. Array Labs and Mitsubishi Electric have also entered into a partnership to develop and bring to market satellite-based maritime and aircraft tracking services for defense and security customers in the Asia Pacific Region.

This investment follows Array’s Series A fundraise, announced in January 2026.

Array Labs and Mitsubishi Electric Partnership

Mitsubishi Electric is one of Japan’s largest defense and aerospace contractors, supplying advanced electronics, radar, and satellite systems to the Japanese Ministry of Defense for over half a century. In February 2026, it was awarded a contract to develop and manufacture Japan’s next-generation defense satellite system.

This partnership brings together Array’s transformative approach with Mitsubishi Electric’s satellite system development capabilities, manufacturing infrastructure, and established relationships with defense and government customers across the Asia-Pacific region. Together, Array and Mitsubishi Electric will bring moving object detection and tracking services to defense and security customers.

“We are very pleased to collaborate with Array Labs, which aims to demonstrate its game-changing AMTI technology. By combining the technological capabilities and maximizing the synergies of our two companies, we expect to strengthen our ability to respond comprehensively to customer needs in the security field, “said Masahiko Arai, Executive Officer, Company President, Defense and Space Systems, Mitsubishi Electric Corporation.

“Mitsubishi Electric Corporation’s deep mission insights and defense relationships across Asia-Pacific make them an ideal partner. We’re excited to work together to turn space-based AMTI into an operational reality, helping humanity better understand the physical world,” said Andrew Peterson, CEO and cofounder of Array Labs.

Array Labs has validated its core formation flying and multistatic technology, and earned competitive research and development contracts with DARPA, the U.S. Navy, and the U.S. Air Force.

About Array Labs
Array Labs is building a new way to understand the physical world. Based in Silicon Valley and backed by Y Combinator, Catapult Ventures, Kompas VC, and Washington Harbour Partners, the company is preparing to launch the world’s first coordinated fleet of radar satellites to deliver high-resolution, continuously updated intelligence about the Earth’s terrain, infrastructure, and activity, operating day or night, through clouds, anywhere on the planet. For more information, visit www.arraylabs.io.

About Mitsubishi Electric Corporation
Mitsubishi Electric Corporation is one of Japan’s largest and most established defense and aerospace contractors, supplying advanced electronics, radar, and satellite systems to the Japanese Ministry of Defense for over half a century. Headquartered in Tokyo, the company operates across defense, aerospace, energy, infrastructure, and industrial applications, and maintains partnerships with major defense primes across the United States and Europe. For more information, visit www.mitsubishielectric.com.

Press & Media Contact

Hannah Sachs
Director of External Affairs
Email: [email protected]

SOURCE Array Labs, Inc.

Open-Source Malloy-Powered Platform Captures the Meaning of Enterprise Data, Delivers It As Context at Runtime to AI Agents, APIs, Analytics Tools and More

BOULDER, Colo., July 28, 2026 — Credible Data, the trusted business context engine for enterprise AI, today announced a significant acceleration in the scale-up of its platform following a $10 million seed round from Gradient, SignalFire and K5 Global, along with angel investors including G2 cofounder & CEO Godard Abel, pandas creator and Composed Ventures General Partner Wes McKinney, Snowplow Analytics CEO and co-founder Alex Dean, SV Angel and others. Built on Malloy, an open-source semantic modeling language, Credible’s platform turns organization-specific governed metrics, definitions, entities, and relationships into executable business context that AI agents and applications can query, reuse and trust at scale.

Enterprises have made rapid progress giving AI agents access to unstructured and semi-structured data through documents and knowledge bases. Much of the data that actually runs the business, though, still lives in data warehouses such as Google BigQuery, Snowflake or Postgres. For AI to use this structured data reliably, it needs more than access to rows and columns; it needs the governed business meaning behind the data, including how metrics are defined, how entities relate, which rules apply, and who is allowed to see what. Without that business context, AI agents can produce inconsistent or incorrect answers from the same underlying data, undermining enterprise trust in AI.

Credible Data’s context engine solves this problem by analyzing how an enterprise actually uses its data – informed by real queries and edge cases surfaced during use – to generate a universal, governable semantic model of organization-specific business context using Malloy. Credible Data’s platform makes all of this context available to AI agents, analytics tools and other systems at runtime, enabling organizations to achieve trusted results from every element of their tech stacks while avoiding vendor lock-in and ensuring industry-leading flexibility and agility.

Credible Data CEO and founder Kyle Nesbit said, “Every organization attaches its own meaning to its data — even a term as familiar as ‘revenue’ can mean completely different things from one company to the next. AI can’t be trusted with enterprise data until it understands that meaning. The winners in enterprise AI will be the ones who deliver their data’s meaning as context wherever decisions get made, without locking themselves into a single vendor’s stack. That’s what we’ve built at Credible Data.”

Credible Data takes Malloy’s semantic modeling foundation to enterprise scale, adding the security, role-based access controls, governance, reliability, auditability, and operational safeguards required for mission-critical analytics and high-volume agentic AI workloads.

Gradient General Partner Zach Bratun-Glennon said, “Existing data warehouse and pipeline solutions were never built for AI. As enterprises rush to deploy AI throughout their organizations, they are finding their ability to trust this new technology undermined by conflicting outputs stemming from a lack of consistent meaning applied to their data. Credible Data has built a platform that solves this challenge with unprecedented agility and flexibility, and which we believe will be fundamental in finally achieving trustworthy AI for enterprises.”

Credible Data has assembled an exceptional team with deep industry expertise to pursue its mission. Nesbit previously led Business Intelligence and Data Analytics at Google Cloud and spearheaded Looker’s integration into that platform; prior to that he led Forward Deployed Engineering at Gradient. Additionally, the company’s Head of Product, James Swirhun, spent eight years at Google working on AI/ML products including Gemini; prior to that he was a consultant at Bain & Company.

Peter Nummerdor, SVP of Product for VideoAmp, a Credible Data customer, said, “Our planning and measurement drives decisions by some of the largest companies in the advertising industry, so every insight our AI gives has to be consistent, defensible and grounded in fact. Credible gives our AI systems the same governed understanding of our metrics that our best analysts carry in their heads. That’s what moved us from experimenting with AI to putting it in front of customers with confidence.”

About Credible Data
Credible Data is the engine for trusted business context on enterprise data. Built on Malloy, an open-source semantic modeling language, Credible turns governed metrics, definitions, entities, and relationships into executable context that AI agents and applications can query, reuse, and trust.

Media Contact
Chris Clemens
Nexios Communications Strategies
[email protected]

SOURCE Credible Data

Funding accelerates advancement of first-in-class non-invasive neuromodulation platform to transform the arc of stroke care in ICUs

ST. LOUIS, July 28, 2026 — Aurenar, developer of a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in intensive care unit (ICU) patients, today announced the close of an oversubscribed $5.7 million seed financing round, co-led by the Go Red for Women Venture Fund™, part of American Heart Association Ventures™ — the American Heart Association’s venture capital arm — and Solas BioVentures, with additional participation from BJC Health and Kaleida Capital. Proceeds from the investment round will fund continued advancement toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S. Food and Drug Administration (FDA).

Aurenar’s V-Link™ platform, which recently received breakthrough device designation from the FDA, delivers transauricular vagus nerve stimulation (taVNS) to modulate the body’s inflammatory response to such conditions as subarachnoid hemorrhage (SAH). SAH alone accounts for roughly 7% of all strokes worldwide, leaving approximately 40% of survivors with permanent disability. Initially developed to respond to stroke and broader neurocritical-care challenges, V-Link has the potential to expand into additional high-impact indications in critically ill patients.

Inflammation is a central driver of the secondary injury that worsens outcomes in stroke, subarachnoid hemorrhage, and other critical illnesses. Modulating this cascade non-invasively in the ICU addresses a significant unmet need — and a meaningful opportunity to change recovery trajectories for many patients experiencing the most acute, high-risk conditions that also increase hospital costs.

The company was founded based on research from Dr. Eric Leuthardt, Dr. Anna Huguenard, and colleagues at Washington University School of Medicine in St. Louis. The randomized SAH trial they conducted demonstrated that taVNS reduced moderate-to-severe vasospasm by more than 40%, lowered pro-inflammatory cytokines, and improved functional outcomes. A companion analysis also showed a 20% drop in 30-day modifiable hospitalization costs directly linked to the method. A separate large-vessel occlusion (LVO) ischemic stroke trial showed consistent anti-inflammatory effects and a clean safety profile.

V-Link’s simple, wireless design makes it easier for neuro-intensive care physicians and ICU nursing staff to use the device without extensive training and supports faster onboarding and clinical adoption.

“We are excited to support Aurenar because stroke is a major cause of mortality and long-term disability in women, who face a disproportionately higher prevalence of subarachnoid hemorrhage. Their V-Link product promises to offer a pathway to improve recovery for all patients and especially for women who often experience higher rates of post-stroke complications,” said Tracy Warren, Sr. Managing Director, Go Red for Women Venture Fund, part of the American Heart Association Ventures family of funds. “The potential for use with other conditions that trigger the body’s inflammatory response, which also disproportionately affect women, makes V-Link the kind of scalable innovation our fund was created to accelerate.”

“This seed close marks a pivotal moment for Aurenar,” said Dr. Leuthardt, Founder and Chief Executive Officer of Aurenar and a professor of neurosurgery at WashU Medicine. “With the support of the Go Red for Women Venture Fund, Solas BioVentures, and our broader investor group, we are positioned to advance from early-stage neurotechnology to a pivotal-trial-ready company. Every dollar of this round is committed to milestones that help us improve outcomes for patients in the most critical moments of their care.”

“At WashU, we are reinforcing pathways that convert bold scientific ideas into real-world solutions,” said Doug Frantz, PhD, Vice Chancellor for Innovation and Commercialization, Washington University. “This neuromodulation platform is yet another example of the strength of WashU’s innovation ecosystem, and Dr. Leuthardt’s progress with Aurenar is bringing us closer to delivering meaningful advances to some of our most critically ill patients.”

About Aurenar
Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company’s transauricular vagus nerve stimulation (taVNS) device targets the body’s inflammatory response to improve outcomes, lower total cost of care, and transform critical care management. Beginning with the impacts of stroke, Aurenar’s platform is positioned to expand to address multiple high-acuity indications. Aurenar is headquartered in St. Louis, Missouri. Learn more at www.aurenar.com.

About Go Red Fund and American Heart Association Ventures
The Go Red for Women Venture Fund™ invests in market-driven solutions across a spectrum of heart health, brain health and related conditions to improve health for women. The Fund invests in early-stage companies whose products and services improve access, diagnosis and treatment for women. Through focused investment that translates science into action, the Go Red Fund is sparking real-world change and making a measurable difference in women’s lives.

The Go Red Venture Fund is part of American Heart Association Ventures, the venture capital platform of the American Heart Association.

About Solas BioVentures

Solas BioVentures is a venture capital firm investing in early- and development-stage biopharmaceutical, medical device, and digital health companies. Founded by physicians, scientists, and operators, the firm pairs deep clinical expertise and a patient-centric approach to funding technologies advancing the standard of care. Solas is headquartered in Chattanooga, Tennessee, with a presence in Research Triangle Park, North Carolina. Learn more at www.solasbio.com.

Solas BioVentures Management, LLC is an SEC-registered investment adviser. Registration does not imply a certain level of skill or training. For informational purposes only. Past performance is not indicative of future results. Investing involves risk, including the possibility of loss of principal. Learn more at https://adviserinfo.sec.gov/firm/summary/322344.

SOURCE Aurenar

LOUISVILLE, Colo., July 28, 2026 — Alpen High Performance Products (Alpen), a leading American manufacturer of high efficiency window solutions, today announced the initial $6 million closing of a targeted $10 million, Series B funding round, which was led by Inherent Capital and Arborview Capital. The investment will be used to further scale Alpen’s manufacturing operations and to meet surging market demand for the company’s advanced building materials.

Over the past two and a half years, Alpen has achieved over 50 percent growth. This expansion was driven by strong market adoption of its core innovations, specifically its advanced thin glass insulated glass units (IGUs), Alpen’s Winsert secondary glazing solutions, and its high performance fiberglass windows.

“This capital injection is a massive vote of confidence in our team and the work we do every day,” said Andrew Zech, CEO of Alpen. “Over the last three years, we have fundamentally transformed how Alpen operates. We have transitioned from a bespoke manufacturer into a national brand with a scaled and standardized product suite, and this funding ensures we have the necessary operating capital to meet growing demand.”

Alpen’s recent growth has been fueled by a series of strategic operational and commercial milestones. The company successfully installed automated manufacturing capabilities to manufacture its thin glass IGUs with insulating performance up to R15, and its industry-leading fiberglass and uPVC window, door, and secondary glazing systems. In addition, Alpen has professionalized its sales organization with a sharp focus on commercial go-to-market structures. As a result, sales figures for Winsert and its commercial windows have grown by more than four times.

Alpen also successfully launched third-party sales of its thin glass IGUs, and is actively supplying a number of other North American window and door manufacturers with this critical technology. To support this ongoing innovation and production scale, the company has built strong engineering, customer success, and IT teams that are dedicated to keeping Alpen at the forefront of advanced window and door technology, and to providing superior customer service.

With this initial Series B closing, Alpen is well positioned to optimize its manufacturing operations, expand its capacity, and maintain the strategic direction that has fueled its recent success.

About Alpen
For over forty years, Alpen High Performance Products has pursued a quest to transform the built environment by designing North America’s most energy efficient windows, doors and architectural glass. We specialize in leveraging advanced materials and innovative design to ensure exceptional performance for both commercial and residential applications. Our products rank among the highest performing and most durable solutions in North America and beyond. Please visit Alpen’s website to learn more.

Media Contact:

Reid Wegley

(206) 963-4167

[email protected] 

SOURCE Alpen High Performance Products

The venture financing and AMED grant funding position CORE to accelerate development of novel lineage-based oncology therapies for patients around the world.

BOSTON and TOKYO and SUZHOU, China, July 28, 2026 — CORE Biomedicine, a biotechnology company pioneering lineage-based precision oncology therapeutics, today announced the completion of a $21 million Series A financing. The round is co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, alongside participation from InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. CORE’s lineage-based approach is designed to identify and target core oncology drivers with precision while expanding the potential patient populations that may benefit from these novel therapies.

In addition to venture financing, CORE Biomedicine Japan, a wholly owned subsidiary, has been awarded a grant under the Strengthening Program for Pharmaceutical Startup Ecosystem, a highly competitive initiative run by the Japan Agency for Medical Research and Development (AMED) to accelerate innovative biotech companies and support Japan’s biopharma ecosystem. This grant supports CORE’s research and development activities while strengthening collaborations through partnerships with Japanese universities, hospitals and the overall biopharma community.

These resources will advance CORE’s lead programs through discovery and early clinical development. CORE is building an innovative precision medicine company by leveraging the rapidly evolving global biotech ecosystem.

“This venture financing and AMED’s support represent a major milestone for CORE Biomedicine and validate our vision for a new generation of oncology medicines,” said Dr. Ping Zhu, Co-Founder and CEO of CORE Biomedicine. “We are grateful to our investors and partners as we advance our programs toward the clinic with the goal of bringing transformative therapies to patients globally.”

“CORE Biomedicine’s lineage-based approach addresses a fundamental challenge in cancer biology that genomics alone cannot solve,” said Makoto (Mark) Ohori, PhD, Partner and Chief Investment Officer, Life Sciences, UTokyo Innovation Platform Co., Ltd. “We are proud to co-lead this financing and look forward to supporting the CORE Biomedicine team as they advance their programs toward the clinic.”

“Elikon Venture highly recognizes the CORE Biomedicine team for their distinctive insights and extensive R&D experience in oncology area. We are delighted to witness the company’s fast-growing trajectory. We look forward to collaborating with CORE Biomedicine to advance its cutting-edge drug pipeline and address unmet medical needs for global patients by delivering better clinical benefits.”

About CORE Biomedicine

Founded by former leaders of H3 Biomedicine, CORE Biomedicine is developing the next generation of precision medicines by going beyond genomics. The company’s lineage-based therapeutic approach targets core biological pathways that define cancer cell identity, enabling the discovery of first- and best-in-class therapies with the potential to benefit broader patient populations.

About UTokyo Innovation Platform Co., Ltd. (UTokyo IPC)

UTokyo Innovation Platform Co., Ltd. (UTokyo IPC) is a venture capital firm wholly owned by the University of Tokyo, established in 2016 to strengthen Japan’s global industrial competitiveness through startup investment and ecosystem building. UTokyo IPC supports the creation and growth of university-affiliated startups through investment and ecosystem-building activities.

About Elikon Venture

Founded in 2021, Elikon Venture is a global early-stage biotech investor dedicated to addressing unmet clinical needs. We partner with ambitious entrepreneurs and pioneering scientists, bringing breakthrough technologies. Elikon brings unique insights to the biopharma market and specialize in connecting our global portfolio companies to China’s top-tier industry resources and strategic services.

SOURCE CORE Biomedicine

– Claros Technologies recauda 55 millones de dólares en financiación Serie B para acelerar la comercialización global de su tecnología de destrucción de PFAS

Esta financiación busca satisfacer la creciente demanda comercial de la tecnología patentada ClarosTechUV™ y respaldar la expansión del laboratorio móvil ClarosLabs™, tras los innovadores resultados en la remediación de aguas subterráneas contaminadas con PFAS y el endurecimiento de las regulaciones globales sobre PFAS

MINNEAPOLIS, 28 de julio de 2026 — Claros Technologies, Inc. (Claros), líder mundial en soluciones de destrucción y análisis de PFAS (sustancias perfluoroalquiladas y polifluoroalquiladas, comúnmente conocidas como “sustancias químicas permanentes”), ha informado hoy del éxito en el cierre de una ronda de financiación Serie B de 55 millones de dólares, que incluye la financiación mediante pagarés convertibles anunciada previamente por la compañía. Esta financiación va a servir para poder acelerar la comercialización global del sistema patentado de destrucción de PFAS ClarosTechUV™, ampliar ClarosLabs™, fortalecer la fabricación y las operaciones, y respaldar la creciente demanda de fabricantes industriales, empresas de remediación, servicios públicos y agencias gubernamentales que buscan la destrucción permanente de PFAS y soluciones analíticas avanzadas.

La ronda de financiación Serie B fue liderada por Treehouse Family Capital LLC, con la participación de Daikin America, Inc., Veralto, Bush Foundation, Nord Asset Management y Saint Paul & Minnesota Foundation, además del apoyo continuo de los inversores existentes. Esta financiación reunió a un grupo diverso de inversores institucionales y estratégicos de los sectores industrial, medioambiental y tecnológico, un reflejo del amplio reconocimiento del dinamismo comercial de Claros, su plataforma tecnológica diferenciada y la importante oportunidad global que surge en torno a la destrucción permanente de PFAS y las soluciones analíticas.

La tecnología de Claros permite el uso continuado de PFAS en aplicaciones críticas en sectores clave, como la fabricación de semiconductores, la industria aeroespacial, la farmacéutica y la sanitaria, entre otras, al tiempo que posibilita la destrucción de PFAS a escala industrial. El resultado es una solución que impulsa tanto la innovación como la protección del medio ambiente.

La financiación permitirá ampliar la capacidad de fabricación, realizar despliegues comerciales adicionales en Norteamérica, Europa y Asia, continuar el desarrollo de productos, expandir ClarosLabs™, contratar estratégicamente personal para las áreas de ingeniería y operaciones comerciales, e invertir continuamente en atención al cliente y desarrollo de aplicaciones. Esta financiación posiciona a Claros para satisfacer la creciente demanda global, a medida que las industrias y los gobiernos transitan cada vez más de la gestión de PFAS hacia tecnologías de destrucción permanente.

Michelle Bellanca, consejera delegada y cofundadora de Claros Technologies, destacó la importancia del reciente impulso de la empresa y el capital obtenido para respaldar su próxima fase de crecimiento:

“Durante el último año, Claros ha dado el salto de la tecnología innovadora a una exitosa realidad comercial. Nuestro trabajo con importantes fabricantes industriales ha demostrado que la destrucción permanente de todas las especies de PFAS objetivo puede operar de manera confiable, eficiente y rentable a escala comercial, mientras que nuestros recientes resultados en la remediación de aguas subterráneas han demostrado que la misma tecnología funciona excepcionalmente bien en aplicaciones ambientales complejas. Junto con la rápida evolución e implementación de las regulaciones sobre PFAS en todo el mundo, estos hitos han ampliado fundamentalmente nuestras oportunidades. Esta financiación nos proporciona los recursos para acelerar los despliegues comerciales a nivel mundial, continuar avanzando en nuestra tecnología y ayudar a nuestros clientes a abordar uno de los desafíos ambientales más importantes del mundo”.

Jack Cogen, responsable de Treehouse Family Capital LLC, añadió:

“Las empresas tecnológicas más prometedoras llegan a un punto de inflexión donde la pregunta ya no es si la tecnología funciona, sino con qué rapidez puede implementarse a gran escala. Creemos que Claros ha alcanzado ese punto. Claros ha demostrado la eficacia de su tecnología en condiciones comerciales reales. Ha desarrollado una plataforma integrada que combina la destrucción de PFAS con servicios analíticos y está expandiéndose comercialmente en el momento preciso. Con el impulso normativo acelerándose en todo el mundo, vemos la oportunidad de contribuir a la creación de una de las empresas de tecnología ambiental más importantes de la próxima década y más allá”.

Claros ha alcanzado varios hitos comerciales clave que han consolidado a ClarosTechUV™ como la tecnología líder y probada en campo para la destrucción de PFAS. En diciembre de 2025, la compañía, en colaboración con Daikin America, completó con éxito una de las mayores demostraciones mundiales de destrucción de PFAS en aguas de procesos industriales, logrando una destrucción superior al 99,99% en compuestos PFAS de cadena larga, corta y ultracorta. En abril de 2026, Claros demostró una destrucción ≥99,99% de compuestos PFAS específicos en aplicaciones de remediación de aguas subterráneas utilizando un concentrado derivado de aproximadamente un millón de galones (3,8 millones de litros) de agua subterránea, lo que valida la escalabilidad de la tecnología tanto en la fabricación industrial como en aplicaciones de remediación ambiental.

De forma conjunta, estos hitos marcan la transición de Claros desde la validación comercial hasta su amplia implementación en el mercado, lo que la posiciona para ofrecer comercialmente su plataforma integrada de destrucción de PFAS y servicios analíticos en los mercados de fabricación industrial, remediación ambiental y cumplimiento normativo a nivel mundial.

La financiación se produce en un momento en que el panorama normativo global en torno a los PFAS continúa evolucionando rápidamente. En Europa, los responsables políticos están impulsando amplias restricciones a los PFAS bajo el marco propuesto del Reglamento REACH, al tiempo que evalúan exenciones específicas para usos esenciales. En Estados Unidos, las agencias federales y estatales siguen ampliando los estándares de agua potable, los requisitos de descarga industrial y los programas de remediación. A medida que estos requisitos normativos se vuelven más exhaustivos, las organizaciones buscan cada vez más no solo tecnologías de destrucción permanente de PFAS, sino también servicios analíticos avanzados capaces de detectar, cuantificar y documentar con precisión los PFAS para respaldar el cumplimiento normativo. En conjunto, estas tendencias convergentes impulsan la demanda tanto de la tecnología de destrucción de PFAS ClarosTechUV™ como de ClarosLabs™, la oferta de servicios analíticos de PFAS de la compañía.

Acerca de Claros Technologies

Fundada en 2018 y con sede en Minneapolis, Minnesota, Estados Unidos, Claros Technologies es líder mundial en la mitigación de PFAS, con dos divisiones principales. La división ClarosTech™ se centra exclusivamente en la destrucción permanente de PFAS, ofreciendo sistemas asequibles, de alto caudal, escalables y listos para su uso en campo que destruyen compuestos PFAS de cadena larga, corta y ultracorta. ClarosLabs™, la división analítica de la compañía acreditada según la norma ISO/IEC 17025:2017, es un laboratorio comercial líder dedicado exclusivamente a la detección, cuantificación y evaluación de la exposición a PFAS. La misión de Claros es eliminar los PFAS del medio ambiente. Claros está eliminando la persistencia de los PFAS y destruyéndolos definitivamente.

Contacto para medios
Kari Finkler
[email protected]

Financing to meet rapidly growing commercial demand for proprietary ClarosTechUV™ technology and support expansion of ClarosLabs™ mobile laboratory, following breakthrough PFAS groundwater remediation results and tightening global PFAS regulations.

MINNEAPOLIS, July 28, 2026 — Claros Technologies, Inc. (Claros), a global leader in destruction and analytical solutions for PFAS — per- and polyfluoroalkyl substances, commonly known as “forever chemicals” — today announced the successful closing of a $55 million Series B financing, inclusive of the company’s previously announced convertible note financing. The financing will accelerate the global commercialization of the proprietary ClarosTechUV™ PFAS Destruction System, expand ClarosLabs™, strengthen manufacturing and operations, and support growing demand from industrial manufacturers, remediation firms, utilities, and government agencies seeking permanent PFAS destruction and advanced analytical solutions.

The Series B financing was led by Treehouse Family Capital LLC, with participation from Daikin America, Inc., Veralto, Bush Foundation, Nord Asset Management, and Saint Paul & Minnesota Foundation, together with continued support from existing investors. The financing brought together a diverse group of institutional and strategic investors from across the industrial, environmental, and technology ecosystem, reflecting broad recognition of Claros’ commercial momentum, differentiated technology platform, and the significant global opportunity emerging around permanent PFAS destruction and analytical solutions.

Claros’ technology supports the continued use of PFAS in critical applications across key industries, including semiconductor manufacturing, aerospace, pharmaceuticals and healthcare, among others, while enabling the destruction of PFAS at an industrial scale. The result is a solution that advances both innovation and environmental stewardship.

The financing will support expanded manufacturing capacity, additional commercial deployments throughout North America, Europe, and Asia, continued product development, expansion of ClarosLabs™, strategic hiring across engineering and commercial operations, and ongoing investment in customer support and application development. The financing positions Claros to meet accelerating global demand as industries and governments increasingly transition from PFAS management toward permanent destruction technologies.

Michelle Bellanca, Chief Executive Officer and Co-Founder of Claros Technologies, underscored the significance of the company’s recent momentum and the capital secured to support its next phase of growth:

“Over the past year, Claros has crossed the threshold from breakthrough technology to successful commercial reality. Our work with major industrial manufacturers has demonstrated that permanent destruction of all targeted PFAS species can operate reliably, efficiently and cost-effectively at commercial scale, while our recent groundwater remediation results have shown that the same technology performs exceptionally well across complex environmental applications. Coupled with the rapid evolution and implementation of PFAS regulations around the world, these milestones have fundamentally expanded our opportunity. This financing gives us the resources to accelerate commercial deployments globally, continue advancing our technology, and help customers address one of the world’s most significant environmental challenges.”

Jack Cogen, Manager of Treehouse Family Capital LLC, added:

“The most exciting technology companies eventually reach an inflection point where the question is no longer whether the technology works, but how quickly it can be deployed at scale. We believe Claros has reached that point. Claros has demonstrated that its technology is effective under real-world commercial conditions. Claros has built an integrated platform that combines PFAS destruction with analytical services and is scaling commercially at exactly the right time. With regulatory momentum accelerating around the world, we see an opportunity to help build one of the defining environmental technology companies of the next decade and beyond.”

Claros has achieved several key commercial milestones that have established ClarosTechUV™ as the leading field-proven PFAS destruction technology. In December 2025, the company, in partnership with Daikin America, successfully completed one of the world’s largest in-field PFAS destruction demonstrations of industrial process water while achieving greater than 99.99% destruction across long-, short-, and ultra-short chain PFAS compounds. In April 2026, Claros demonstrated ≥99.99% destruction of targeted PFAS compounds in groundwater remediation applications using concentrate derived from approximately one million gallons (3.8 million liters) of groundwater, validating the scalability of the technology across both industrial manufacturing and environmental remediation applications.

Together, these milestones mark Claros’ transition from commercial validation to broad market deployment, positioning the company to commercially offer its integrated PFAS destruction and analytical services platform across industrial manufacturing, environmental remediation, and regulatory compliance markets worldwide.

The financing comes as the global regulatory landscape surrounding PFAS continues to evolve rapidly. In Europe, policymakers are advancing broad PFAS restrictions under the proposed REACH Regulation framework while evaluating sector-specific exemptions for essential uses. In the United States, federal and state agencies continue expanding drinking water standards, industrial discharge requirements, and remediation programs. As these regulatory requirements become more comprehensive, organizations are increasingly seeking not only permanent PFAS destruction technologies, but also advanced analytical services capable of accurately detecting, quantifying, and documenting PFAS to support regulatory compliance. Together, these converging trends are driving demand for both the ClarosTechUV™ PFAS destruction technology and ClarosLabs™, the company’s PFAS analytical services offering.

About Claros Technologies

Founded in 2018 and based in the United States in Minneapolis, Minnesota, Claros Technologies is a global leader in PFAS mitigation, with two core divisions. The ClarosTech™ division focuses exclusively on the permanent destruction of PFAS, offering affordable, high-flow, scalable, and field-ready systems that destroy long, short, and ultra-short chain PFAS compounds. ClarosLabs™, the company’s ISO/IEC 17025:2017 accredited analytical division, is a leading commercial laboratory dedicated solely to PFAS detection, quantification, and exposure assessment. Claros is on a mission to eliminate PFAS from the environment. Claros is taking the ‘forever’ out of “forever chemicals” and destroying PFAS for good.

Media Contact
Kari Finkler
[email protected]